Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19

  • Antimicrob Agents Chemother. 2022 Dec 15;e0135322. doi: 10.1128/aac.01353-22.
Elizabeth E Zumbrun  1 ,  Chengzi I Kaku  2 ,  Lukas Dillinger  3 ,  Samantha E Zak  1 ,  Ana I Kuehne  1 ,  Russel R Bakken  1 ,  Jeffrey W Koehler  1 ,  Korey L Delp  1 ,  Christopher P Stefan  1 ,  Raina Kumar  1 ,  Jeffrey R Kugelman  1 ,  Alicia M Moreau  1 ,  Xiankun Zeng  1 ,  John M Dye  1 ,  Andrew S Herbert  1 ,  Kristin Narayan  3 ,  Laura M Walker  3
Affiliations
  • 1. U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.
  • 2. Adimab LLC, Lebanon, New Hampshire, USA.
  • 3. Invivyd, Inc., Waltham, Massachusetts, USA.
PMID: 36519929 DOI: 10.1128/aac.01353-22
Abstract

Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. In both Syrian golden hamster and rhesus macaque models, prophylactic administration of a single dose of adintrevimab provided protection against SARS-CoV-2/WA1/2020 Infection in a dose-dependent manner, as measured by significant reductions in lung viral load and virus-induced lung pathology, and by inhibition of viral replication in the upper and lower respiratory tract.

Keywords
ADG20; COVID-19; SARS-CoV-2; adintrevimab; animal model; monoclonal antibody; preclinical; prevention.
Products